{
    "clinical_study": {
        "@rank": "161490", 
        "arm_group": {
            "arm_group_label": "erlotinib", 
            "arm_group_type": "Experimental", 
            "description": "This protocol is a phase 1, single arm, open label study of combination daily low dose erlotinib plus twice weekly high dose erlotinib in patients with EGFR-Mutant lung cancer who have not yet received erlotinib or gefitinib. Six dose levels are planned for escalation, with the pulse dose erlotinib increasing."
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to test the safety of different ways of taking erlotinib. The\n      investigators want to find out what effects, good and/or bad, combination daily low dose and\n      twice weekly high dose erlotinib has on the patient and lung cancer."
        }, 
        "brief_title": "Low Dose Daily Erlotinib in Combination With High Dose Twice Weekly Erlotinib in Patients With EGFR-Mutant Lung Cancer", 
        "completion_date": {
            "#text": "October 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "EGFR-Mutant Lung Cancer", 
        "condition_browse": {
            "mesh_term": "Lung Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  MSKCC pathologically-proven diagnosis of EGFR-Mutant locally advanced Stage III not\n             amenable to definitive, curative treatment or Stage IV or recurrent non-small cell\n             lung cancer\n\n          -  No prior treatment with erlotinib, gefitinib, or other EGFR tyrosine kinase\n             inhibitors\n\n          -  Age \u2265 18 years\n\n          -  Measurable (RECIST 1.1) indicator lesion not previously irradiated.\n\n          -  Karnofsky Performance Status \u2265 70%\n\n          -  Ability to take oral medications\n\n          -  A negative serum pregnancy test obtained within 4 weeks prior to the start of\n             treatment in all women of child-bearing potential.\n\n          -  All women of child bearing potential and sexually active men must agree to use\n             adequate methods of birth control throughout the study which includes use of oral\n             contraceptives with an additional barrier methods, double barrier methods,\n             Depo-Provera, permanent sterilization of patient or partner or total abstinence.\n\n        Exclusion Criteria:\n\n          -  1. Inadequate recovery from any toxicity related to prior treatment (to Grade 2 or\n             baseline).\n\n          -  Inadequate hematologic function defined as ANC < 1000 cells/mm\u00b3, Platelet count\n             <75,000/mm\u00b3 or Hemoglobin <9.0g/dL.\n\n          -  Inadequate hepatic function defined by AST/ALT >3x upper limit of normal (ULN), Total\n             bilirubin>2x ULN, Alkaline phosphatase >3x ULN.\n\n          -  Symptomatic brain metastasis requiring radiation therapy or escalating doses of\n             steroids.\n\n          -  Patients with clinically stable brain metastases (previously treated or untreated)\n             are eligible.\n\n          -  Women who are breastfeeding or pregnant.\n\n          -  Any evidence of clinically active interstitial lung disease."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "70", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 15, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01967095", 
            "org_study_id": "12-278"
        }, 
        "intervention": {
            "arm_group_label": "erlotinib", 
            "description": "Cycle 1, week 1 (D1-D7) will consist of pulse dose erlotinib on D1 & D2 without daily low dose erlotinib on D3-7. For all subsequent weeks, patients will take high dose erlotinib on D1 & D2, & will receive erlotinib 50 mg oral daily x 5 days on days 3-7. On days 1 & 2, patients will take one of the following doses of erlotinib, depending on the dose cohort they are enrolled in: Dose level 1 600 mg oral daily on D1, D2 Dose level 2 750 mg oral daily on D1, D2 Dose level 3 900 mg oral daily on D1, D2 Dose level 4 1050 mg oral daily on D1, D2. An additional Dose -1 (pulse dose erlotinib on D1, D2 with 25 mg oral daily x 5 days in D3-D7) will be reserved, in the unlikely situation that Dose 1 is proved too toxic. If Dose -1 is tolerated well (600mg oral daily D1, D2 & 25mg oral daily D3-D7), pulse dose escalation can continue as described above, with erlotinib at the daily low dose of 25 mg oral on D3-D7.", 
            "intervention_name": "erlotinib", 
            "intervention_type": "Drug", 
            "other_name": [
                "The assigned dosing schedule will be repeated weekly x 3 to complete a 3 week", 
                "(21 day) cycle. Cycle 1 will be 4 weeks to account for one week of lead in", 
                "pulse dose erlotinib only."
            ]
        }, 
        "intervention_browse": {
            "mesh_term": "Erlotinib"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Erlotinib", 
            "12-278"
        ], 
        "lastchanged_date": "April 23, 2014", 
        "link": {
            "description": "Memorial Sloan-Kettering Cancer Center", 
            "url": "http://www.mskcc.org/"
        }, 
        "location": [
            {
                "contact": {
                    "last_name": "Helena Yu, MD", 
                    "phone": "646-888-4274"
                }, 
                "facility": {
                    "address": {
                        "city": "Basking Ridge", 
                        "country": "United States", 
                        "state": "New Jersey"
                    }, 
                    "name": "Memoral Sloan Kettering Cancer Center"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Helena Yu, MD", 
                    "phone": "646-888-4274"
                }, 
                "facility": {
                    "address": {
                        "city": "Commack", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "11725"
                    }, 
                    "name": "Memorial Sloan-Kettering Cancer Center @ Suffolk"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Helena Yu, MD", 
                    "phone": "646-888-4274"
                }, 
                "contact_backup": {
                    "last_name": "Gregory Riely, MD, PhD", 
                    "phone": "646-888-4199"
                }, 
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10065"
                    }, 
                    "name": "Memorial Sloan Kettering Cancer Center"
                }, 
                "investigator": {
                    "last_name": "Helena Yu, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Helena Yu, MD", 
                    "phone": "646-888-4274"
                }, 
                "facility": {
                    "address": {
                        "city": "Rockville Centre", 
                        "country": "United States", 
                        "state": "New York"
                    }, 
                    "name": "Memorial Sloan-Kettering at Mercy Medical Center"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Helena Yu, MD", 
                    "phone": "646-888-4274"
                }, 
                "facility": {
                    "address": {
                        "city": "Sleepy Hollow", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10591"
                    }, 
                    "name": "Memoral Sloan Kettering Cancer Center at Phelps"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase 1 Trial of Low Dose Daily Erlotinib in Combination With High Dose Twice Weekly Erlotinib in Patients With EGFR-Mutant Lung Cancer", 
        "overall_contact": {
            "last_name": "Helena Yu, MD", 
            "phone": "646-888-4274"
        }, 
        "overall_contact_backup": {
            "last_name": "Gregory Riely, MD, PhD", 
            "phone": "646-888-4199"
        }, 
        "overall_official": {
            "affiliation": "Memorial Sloan-Kettering Cancer Center", 
            "last_name": "Helena Yu, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "October 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The study will use a standard 3+3 dose escalation design. Three to six patients will need to be enrolled at each dose level and assessed for DLT for 1 full cycle (28 days for cycle 1) before dose escalation decision is made.", 
            "measure": "to determine the maximum tolerated dose (MTD)", 
            "safety_issue": "No", 
            "time_frame": "1 year"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01967095"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Toxicity will be graded according to NCI CTCAE, version 4.0. The analysis of safety/tolerability data will be descriptive; toxicity events will be individually tabulated.", 
                "measure": "to evaluate the safety profile", 
                "safety_issue": "Yes", 
                "time_frame": "1 year"
            }, 
            {
                "description": "Progression free survival (PFS) is defined as the duration of time from first treatment to time of progression or death, whichever occurs first.", 
                "measure": "Progression Free Survival (PFS)", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }, 
            {
                "description": "sum of complete responses and partial responses according to RECIST 1.1", 
                "measure": "Response rate (RR)", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }, 
            {
                "description": "Overall survival (OS) is defined as the duration of time from first treatment to time of death.", 
                "measure": "Overall survival (OS)", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }
        ], 
        "source": "Memorial Sloan-Kettering Cancer Center", 
        "sponsors": {
            "collaborator": {
                "agency": "Astellas Pharma US, Inc.", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Memorial Sloan-Kettering Cancer Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}